Next-Gen Clinical Trials in Parkinson’s Disease: Innovation in Action

Parkinson's disease remains one of the most complex neurodegenerative disorders, with heterogeneous pathology, variable progression, and limited disease-modifying treatments. As our understanding of its molecular underpinnings deepens, the methodologies we use to evaluate new therapies must evolve accordingly. Next-Gen Clinical Trials in Parkinson's Disease: Innovation in Action offers a comprehensive examination of the transformative shifts occurring in clinical trial design, execution, and evaluation for Parkinson's research. This volume explores how emerging technologies, innovative regulatory strategies, and patient-centric frameworks are redefining the landscape of translational neuroscience. Key topics include: Decentralized and Hybrid Trial Designs: Leveraging wearable technologies, remote assessments, and digital platforms to increase participant diversity, real-world data capture, and trial efficiency. Artificial Intelligence and Machine Learning Applications: Enhancing patient stratification, optimizing outcome prediction, and accelerating signal detection across large, multidimensional datasets. Precision Medicine and Biomarker-Driven Approaches: Implementing genetic stratification, fluid and imaging biomarkers, and individualized treatment paradigms to improve therapeutic targeting. Regulatory Innovation: Addressing adaptive trial designs, real-world evidence integration, and evolving regulatory frameworks across global agencies. Participant Engagement and Equity: Prioritizing inclusivity, ethical data collection, and meaningful patient involvement in protocol development and decision-making. Emerging Therapeutic Modalities: A forward-looking analysis of gene therapies, antisense oligonucleotides, immunotherapies, and cell-based interventions currently under investigation. This book is designed for clinicians, neuroscientists, clinical trialists, and regulatory professionals who are engaged in or planning research involving Parkinson's disease. It is also relevant for biopharmaceutical developers, data scientists, and academic institutions aiming to align trial design with the rapidly evolving therapeutic and technological landscape. Next-Gen Clinical Trials in Parkinson's Disease provides both a critical overview of current best practices and a strategic framework for the future of clinical research in Parkinsonian disorders.